Abbott Laboratories (NYSE:ABT) Given New $125.00 Price Target at BTIG Research

Abbott Laboratories (NYSE:ABT) had its price objective lowered by equities researchers at BTIG Research from $134.00 to $125.00 in a report released on Thursday, Benzinga reports. The brokerage currently has a “buy” rating on the healthcare product maker’s stock. BTIG Research’s price target indicates a potential upside of 24.27% from the company’s previous close.

Other analysts also recently issued research reports about the company. Weiss Ratings upgraded Abbott Laboratories from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, September 18th. Robert W. Baird increased their target price on Abbott Laboratories from $121.00 to $123.00 and gave the stock an “outperform” rating in a research note on Thursday. Wells Fargo & Company raised their price target on Abbott Laboratories from $109.00 to $112.00 and gave the company an “overweight” rating in a report on Friday, July 17th. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $130.00 price target on shares of Abbott Laboratories in a research report on Friday, July 17th. Finally, TD Cowen reiterated a “buy” rating and issued a $135.00 price target on shares of Abbott Laboratories in a research note on Friday, October 16th. Two research analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $118.60.

Abbott Laboratories Trading Down 1.8%

NYSE:ABT opened at $100.59 on Thursday. The firm has a market capitalization of $174.06 billion, a P/E ratio of 32.55, a PEG ratio of 1.90 and a beta of 0.59. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97. Abbott Laboratories has a one year low of $81.97 and a one year high of $132.02. The company’s 50-day simple moving average is $105.47 and its 200 day simple moving average is $98.28.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Wednesday, October 21st. The healthcare product maker reported $1.42 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.42. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The business had revenue of $13.01 billion during the quarter, compared to the consensus estimate of $12.99 billion. During the same quarter last year, the firm earned $1.30 earnings per share. The business’s revenue for the quarter was up 14.5% on a year-over-year basis. As a group, analysts forecast that Abbott Laboratories will post 5.53 EPS for the current fiscal year.

Institutional Trading of Abbott Laboratories

Institutional investors have recently added to or reduced their stakes in the business. Ledyard National Bank increased its holdings in Abbott Laboratories by 6.4% in the 3rd quarter. Ledyard National Bank now owns 15,237 shares of the healthcare product maker’s stock worth $1,506,000 after buying an additional 913 shares in the last quarter. Culbertson A N & Co. Inc. lifted its stake in Abbott Laboratories by 0.3% during the 3rd quarter. Culbertson A N & Co. Inc. now owns 90,195 shares of the healthcare product maker’s stock valued at $8,914,000 after acquiring an additional 270 shares during the period. NBT Bank N.A. purchased a new stake in shares of Abbott Laboratories during the 3rd quarter valued at about $9,060,000. Root Financial Partners LLC grew its stake in shares of Abbott Laboratories by 93.7% in the third quarter. Root Financial Partners LLC now owns 7,430 shares of the healthcare product maker’s stock worth $734,000 after acquiring an additional 3,594 shares during the period. Finally, Precedent Wealth Partners LLC grew its stake in shares of Abbott Laboratories by 10.7% in the third quarter. Precedent Wealth Partners LLC now owns 33,354 shares of the healthcare product maker’s stock worth $3,296,000 after acquiring an additional 3,234 shares during the period. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott reported third-quarter adjusted earnings of $1.42 per share, matching the consensus estimate, while revenue increased 14.5% year over year to $13.01 billion, slightly above the $12.99 billion forecast. Comparable sales grew 7%, and the company reaffirmed its full-year adjusted EPS guidance. Abbott Reports Third-Quarter 2026 Results and Reaffirms Full-Year EPS Guidance
• Positive Sentiment: Management announced a tax-free spin-off of its global Nutrition business, which includes brands such as Ensure, Similac, PediaSure, Glucerna and Pedialyte. Abbott expects the transaction to create two more focused companies, potentially accelerating Abbott’s sales growth and expanding its margin profile. Completion is targeted for the end of 2027. Abbott Nutrition Spin-Off Announcement
• Positive Sentiment: New product approvals and the European CE Mark for Abbott’s Cologuard Plus colorectal cancer test broaden the company’s diagnostics opportunity and could support longer-term growth. Abbott Secures Europe CE Mark for Colorectal Cancer Test
• Neutral Sentiment: The planned separation involves a nutrition operation generating approximately $8.5 billion in annual sales. While it may unlock value, investors will need to assess the eventual ownership structure, costs, tax implications and execution risks before determining whether the move improves shareholder returns. Abbott to Carve Out Nutrition Business
• Negative Sentiment: Abbott lowered its 2026 sales-growth outlook, citing weakness in medical devices. That guidance reduction overshadowed revenue growth and the reaffirmed EPS outlook, raising concerns about near-term demand and the company’s valuation. Abbott Lowers 2026 Sales Growth Forecast
• Negative Sentiment: Although adjusted EPS met the broad consensus, it was below the $1.43 estimate tracked by Zacks. The modest earnings shortfall, combined with the lower sales outlook, contributed to the stock’s decline despite higher revenue and expanding margins. Abbott Misses Q3 Earnings Estimates

About Abbott Laboratories

Abbott Laboratories is a global healthcare company that develops, manufactures and markets a broad range of medical products and services. Founded in 1888 by Wallace C. Abbott, the company is headquartered in Abbott Park, Illinois, and serves patients, healthcare providers and consumers in markets around the world.

Abbott operates across four principal businesses: medical devices, diagnostics, nutrition and established pharmaceutical products. Its offerings include glucose-monitoring systems such as FreeStyle Libre; cardiovascular devices, including stents and structural heart products; laboratory and point-of-care diagnostic systems; and branded generic medicines in areas such as gastroenterology, women’s health and cardiometabolic care.

The company’s nutrition portfolio includes infant and pediatric products such as Similac and PediaSure, adult nutritional products such as Ensure, and rehydration products such as Pedialyte.